AMT-676

DRUG2 trials

Sponsors

Multitude Therapeutics Inc.

Conditions

Advanced Solid TumorsColorectal Cancer

Early Phase 1

AMT-676 in Patients With Advanced Solid Tumors

RecruitingNCT06400485

Multitude Therapeutics Inc.Advanced Solid Tumors

Start: 2024-06-18End: 2027-12-31Target: 24Updated: 2026-05-18

Phase 2

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

RecruitingNCT07474727

Multitude Therapeutics Inc.Colorectal Cancer

Start: 2026-04-29End: 2028-02-28Target: 180Updated: 2026-08-27

Related Papers

Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers.

2026-09-09

A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.

Journal of Clinical Oncology2025-05-282 citations